Why MoonLake Immunotherapeutics’s (MLTX) Stock Is Down 10.41%
As of Wednesday, June 24, MoonLake Immunotherapeutics’s MLTX share price has dipped by 10.41%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Commentary & Analysis
Why MoonLake Immunotherapeutics’s (MLTX) Stock Is Up 14.11%
As of Monday, June 22, MoonLake Immunotherapeutics’s MLTX share price has surged by 14.11%, which has investors questioning if this is right time to sell.Michael Rose
Why MoonLake Immunotherapeutics’s (MLTX) Stock Is Up 12.88%
As of Monday, June 22, MoonLake Immunotherapeutics’s MLTX share price has surged by 12.88%, which has investors questioning if this is right time to sell.Tudor Pop
Why MoonLake Immunotherapeutics’s (MLTX) Stock Is Down 5.47%
As of Tuesday, June 02, MoonLake Immunotherapeutics’s MLTX share price has dipped by 5.47%, which has investors questioning if this is right time to buy.Michael Rose
Why MoonLake Immunotherapeutics’s (MLTX) Stock Is Down 6.38%
As of Monday, May 18, MoonLake Immunotherapeutics’s MLTX share price has dipped by 6.38%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | MLTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,523.4 | $252.6 | 51% |
|
| Shares Out (Mil) | 71.3 | 52.3 | 56% |
|
| Institutional Ownership | 85.1% | 92.1% | 53% |
|
| Float (Mil) | 49.1 | 40.2 | 47% |
|
| Beta | 1.01 | 0.95 | 60% |
|
| Avg Daily Volume (000s) | 842 | 455 | 67% |
|
| Price Change (52-week) |
(63.5%) | 52.9% | 11% |
|
| Growth | MLTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (9.9%) | na |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 9 | 9 | |
| Current EPS | ($0.896) | ($3.799) | ($3.372) | |
| Month Ago EPS | ($0.923) | ($3.893) | ($3.473) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($0.899) | ($3.716) | ($3.624) | |
| Year/Year Chg | (8.4%) | 7.7% | (9.8%) | |
| Financials | MLTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($257) | ($43) | 5% |
|
| EPS (TTM) | ($3.867) | ($1.600) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($224) | ($31) | 3% |
|
| Net Cash Flow (TTM) (Mil) | $27 | $5 | 65% |
|
| Long-Term Debt (Q1) (Mil) | $100 | $5 | 44% |
|
| Enterprise Value (Q1) (Mil) | $1,058 | $180 | 42% |
|
| Valuation | MLTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.24 | 2.56 | 79% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | MLTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (56.4%) | (49.8%) | 11% |
|
| ROE | (77.7%) | (55.5%) | 11% |
|
| Liabilities to Assets | 36.6% | 30.3% | 27% |
|
| F-Score | 1 | 3 | 1% |
|
MoonLake Immunotherapeutics did not pass any screens on 7/31/2026.
